3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Prostatic Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
16
Nivolumab
9
atezolizumab
7
Docetaxel
7
Cyclophosphamide
5
durvalumab
4
Ipilimumab
4
Gemcitabine
4
avelumab
3
Specimen Handling
3
Radiotherapy
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Carboplatin
3
temsirolimus
2
spartalizumab
2
sargramostim
2
fludarabine
2
epacadostat
2
enzalutamide
2
cabozantinib
2
aldesleukin
2
abiraterone
2
Therapeutics
2
Standard of Care
2
Radiosurgery
2
Polymerase Chain Reaction
2
Peripheral Blood Stem Cell Transplantation
2
Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Solutions
×
Genitourinary
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled